WallStreetZenWallStreetZen

NASDAQ: RLMD
Relmada Therapeutics Inc Stock

Open Broker Account
$2.68+0.51 (+23.5%)
Updated Dec 9, 2022
RLMD Price
$2.68
Fair Value Price
$4.09
Market Cap
$80.67M
52 Week Low
$1.81
52 Week High
$38.68
P/E
-0.46x
P/B
0.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$153.48M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$106M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

RLMD Overview

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RLMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RLMD ($2.68) is undervalued by 34.55% relative to our estimate of its Fair Value price of $4.09 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RLMD ($2.68) is significantly undervalued by 34.55% relative to our estimate of its Fair Value price of $4.09 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RLMD due diligence checks available for Premium users.

Be the first to know about important RLMD news, forecast changes, insider trades & much more!

RLMD News

Valuation

RLMD fair value

Fair Value of RLMD stock based on Discounted Cash Flow (DCF)
Price
$2.68
Fair Value
$4.09
Undervalued by
34.55%
RLMD ($2.68) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RLMD ($2.68) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RLMD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.46x
Industry
19.37x
Market
21.21x

RLMD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
1.75x
RLMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RLMD's financial health

Profit margin

Revenue
$0.0
Net Income
-$39.4M
Profit Margin
0%
RLMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$187.1M
Liabilities
$20.8M
Debt to equity
0.13
RLMD's short-term assets ($187.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLMD's short-term assets ($187.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RLMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$26.9M
Investing
$31.6M
Financing
$569.1k
RLMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RLMD vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
RLMD$80.67M+23.50%-0.46x0.48x
DRRX$82.94M0.00%-2.60x2.38x
UPXI$73.28M+0.20%-12.75x2.70x
SCTL$72.01M-0.78%-5.29x2.04x
SCYX$69.23M+12.17%-0.96x4.02x

Relmada Therapeutics Stock FAQ

What is Relmada Therapeutics's quote symbol?

NASDAQ: RLMD) Relmada Therapeutics trades on the NASDAQ under the ticker symbol RLMD. Relmada Therapeutics stock quotes can also be displayed as NASDAQ: RLMD.

If you're new to stock investing, here's how to buy Relmada Therapeutics stock.

What is the 52 week high and low for Relmada Therapeutics (NASDAQ: RLMD)?

(NASDAQ: RLMD) Relmada Therapeutics's 52-week high was $38.68, and its 52-week low was $1.81. It is currently -93.07% from its 52-week high and 48.07% from its 52-week low.

How much is Relmada Therapeutics stock worth today?

(NASDAQ: RLMD) Relmada Therapeutics currently has 30,099,203 outstanding shares. With Relmada Therapeutics stock trading at $2.68 per share, the total value of Relmada Therapeutics stock (market capitalization) is $80.67M.

Relmada Therapeutics stock was originally listed at a price of $20.00 in Sep 2, 2015. If you had invested in Relmada Therapeutics stock at $20.00, your return over the last 7 years would have been -86.6%, for an annualized return of -24.96% (not including any dividends or dividend reinvestments).

How much is Relmada Therapeutics's stock price per share?

(NASDAQ: RLMD) Relmada Therapeutics stock price per share is $2.68 today (as of Dec 9, 2022).

What is Relmada Therapeutics's Market Cap?

(NASDAQ: RLMD) Relmada Therapeutics's market cap is $80.67M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Relmada Therapeutics's market cap is calculated by multiplying RLMD's current stock price of $2.68 by RLMD's total outstanding shares of 30,099,203.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.